scholarly journals A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

2019 ◽  
Vol 59 (8) ◽  
pp. 1110-1119 ◽  
Author(s):  
Lesley Taylor ◽  
Julie Crockett ◽  
Bola Tayo ◽  
Gilmour Morrison
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Phase 1 ◽  
Severe Hepatic Impairment ◽  
Open Label ◽  
Parallel Group ◽  
Dose Trial

scholarly journals Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study

2021 ◽  
Author(s):  
Xinhui Chen ◽  
Xiaoming Cui ◽  
Nathalie Pognan ◽  
Michelle Quinlan ◽  
Shruti Kapoor ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Phase 1 ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

scholarly journals A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

2015 ◽  
Vol 56 (3) ◽  
pp. 316-323 ◽  
Author(s):  
Denes Csonka ◽  
Katharine Hazell ◽  
Edward Waldron ◽  
Sebastien Lorenzo ◽  
Vincent Duval ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Phase 1 ◽  
Severe Hepatic Impairment ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

scholarly journals A Phase 1, Open-Label, Evaluation of the Single-Dose Pharmacokinetics of Delafloxacin (DLX) in Subjects With and Without Hepatic Impairment

2015 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
Randall Hoover ◽  
Megan Quintas ◽  
Laura Lawrence ◽  
Sriram Gunda ◽  
Eugene Sun ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Phase 1 ◽  
Open Label

Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning

2020 ◽  
Vol 42 (8) ◽  
pp. 1467-1482.e4 ◽  
Author(s):  
Yoshinobu Nakamaru ◽  
Masae Kakubari ◽  
Kaori Yoshida ◽  
Makoto Akimoto ◽  
Vesna Todorovic ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Severe Hepatic Impairment ◽  
Open Label

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study

2017 ◽  
Vol 55 (01) ◽  
pp. 41-53 ◽  
Author(s):  
Kasra Shakeri-Nejad ◽  
Vassilios Aslanis ◽  
Uday Veldandi ◽  
Anne Gardin ◽  
Andreas Zaehringer ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group ◽  
Different Levels

scholarly journals Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open‐label, single‐dose, parallel‐group study

2019 ◽  
Vol 85 (9) ◽  
pp. 2011-2021 ◽  
Author(s):  
Niladri Chattopadhyay ◽  
Kai Riecke ◽  
Sandra Ligges ◽  
Torsten Zimmermann ◽  
Atef Halabi ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study

2009 ◽  
Vol 31 ◽  
pp. 2459-2469 ◽  
Author(s):  
Ophelia Q.P. Yin ◽  
Neil Gallagher ◽  
Chiaki Tanaka ◽  
Deirdre Fisher ◽  
Venkat Sethuraman ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group
Sign in / Sign up

Export Citation Format

Share Document